Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03279445 |
| Other study ID # |
IRB 17-0998 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
August 9, 2017 |
| Est. completion date |
April 10, 2021 |
Study information
| Verified date |
May 2023 |
| Source |
University of Chicago |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
More than 10 million people worldwide are living with Parkinson's disease (PD). While the
actual number of African American (or Black) patients with PD is unknown, it is clear that
there are racial disparities in the access to health care, diagnosis, treatment and survival
of PD. The lack of clear knowledge on the possibly lower PD prevalence among African
Americans compared to Caucasians further calls for more research in this field. The
University of Chicago Medicine is an ideal facility to study this topic, due to its location
on the South Side of Chicago with a large African American (or Black) population. By
analyzing the demographics, socioeconomics and clinical features of PD patients in our Center
for Research Informatics in African American (or Black) patients compared to the Caucasians
of similar geographical area, the investigators aim to work toward a better understanding of
the unique features of PD in American American (or Black) population, which might help
improve the healthcare among this population in the Chicago and possibly nationwide as well.
Description:
The first portion of the study will be a large medical electronic data based search and
analysis of patients with PD on demographics, socioeconomic status and clinical features of
PD patients. Specifically, we will retrospectively identify PD patients on both races from
the electronic medical database spanned from 1/1/2006 to 10/31/2017 and compared
demographics, socioeconomic status (educations, incomes and insurances), co-morbidities (all
categories, including mood, cognition and psychosis), treatment (medications for parkinsonism
and major non-motor symptoms, and frequency and locations of healthcare) and survival, and
identified factors associated with medication usage and survival.
The second portion was designed to collect more detailed clinical assessments for information
not available in the database and blood draws for genetic or candidate gene mutation
analysis. Unfortunately, this part of the study could not be carried out due to the COVID-19
pandemic, which began shortly after completion of the first portion of the study. These
assessments and analyses would have helped determine if there are significant differences in
the clinical and genetic profiles between the African American (or Black) and Caucasian PD
patients that account for their differences in clinical features and PD prevalence in these
two populations.
